Showing results (1-10 of 160) with videos related to
Sort By:
Pageof 16
Expert Review of Neurotherapeutics|March 19, 2016
Disease activity return after natalizumab cessation in multiple sclerosisMaria Rasenack, Tobias DerfussJournal of Immunology Research|June 6, 2014
Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosisMaria Meira, Claudia Sievers, Francine Hoffmann, et al.BMC Medicine|October 6, 2012
Personalized medicine in multiple sclerosis: hope or reality?Tobias DerfussPlos One|January 7, 2016
Efficacy and Safety of Fingolimod in an Unselected Patient PopulationMaria Rasenack, Jonathan Rychen, Michaela Andelova, et al.Current Opinion in Neurology|April 11, 2012
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?Tobias Derfuss, Edgar MeinlNeurology(R) Neuroimmunology & Neuroinflammation|April 19, 2016
Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML developmentMaria Meira, Claudia Sievers, Francine Hoffmann, et al.Therapeutic Advances in Neurological Disorders|March 16, 2019
The monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosisMartin Diebold, Tobias DerfussSeminars in Hematology|June 18, 2016
Immunological treatment of multiple sclerosisMartin Diebold, Tobias DerfussJournal of Neurovirology|December 6, 2011
Control of HSV-1 latency in human trigeminal ganglia--current overviewKathrin Held, Tobias DerfussNeurology(R) Neuroimmunology & Neuroinflammation|September 18, 2015
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MSMaria Zimmermann, Nicholas S R Sanderson, Maria Rasenack, et al.Pageof 16